<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04703985</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2019/29</org_study_id>
    <nct_id>NCT04703985</nct_id>
  </id_info>
  <brief_title>Evaluation of the Success of Prophylactic Enteral Nutrition in Therapeutic Intensification With Autograft of Autologous Hematopoietic Cells in Hematology</brief_title>
  <acronym>GAGNE</acronym>
  <official_title>Evaluation of the Success of Prophylactic Enteral Nutrition in Therapeutic Intensification With Autograft of Autologous Hematopoietic Cells in Hematology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      When the digestive tract is functional, learned societies recommend the use of a nutritional&#xD;
      support by enteral feeding. Indeed, it has many advantages (maintenance of gut trophicity,&#xD;
      reduction of the risk of infection by reducing the incidence of bacterial&#xD;
      translocations,...). It has been used for about fifteen years in hematology departments and&#xD;
      offers promising results in the context of allogeneic transplantation with prospective trials&#xD;
      in progress (NEPHA study). However, its tolerance has not been studied during autologous&#xD;
      transplantation. This study aims to assess the success of enteral nutrition in this setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the literature, there are many studies on the nutritional support to be used during&#xD;
      allografts, that highlight the superiority of enteral nutrition over parenteral nutrition in&#xD;
      terms of reducing co-morbidities.&#xD;
&#xD;
      Enteral nutrition is the nutritional support recommended by learned societies for therapeutic&#xD;
      intensification with autograft of autologous hematopoietic cells in hematology. Nevertheless,&#xD;
      enteral nutrition presents difficulties in its implementation and failures (refusal of&#xD;
      patients, probes vomiting, neutropenic colitis, etc.), requiring the use of parenteral&#xD;
      nutrition in case of failure.&#xD;
&#xD;
      In this context, the study proposes to assess the success and effectiveness of enteral&#xD;
      nutrition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Success rate of enteral feeding</measure>
    <time_frame>From admission to recovery from aplasia (or transfer to the intensive care unit or death)</time_frame>
    <description>Enteral Nutrition will be considered as a success if : TEI / ER &gt; 70%. On average until recovery from aplasia (or transfer to the intensive care unit or death).&#xD;
TEI : Total Energy Intake (per-os + enteral nutrition + glucose solutions) ER : Energy Requirement (assessed patient needs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Causes of failure of enteral nutrition</measure>
    <time_frame>From admission to recovery from aplasia (an average of 3 weeks)</time_frame>
    <description>All causes of primary or secondary failure that necessitated the cessation of enteral nutrition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of total energy intake</measure>
    <time_frame>Every day from admission to discharge (an average of 4 weeks)</time_frame>
    <description>All sources of energy intake (per-os, enteral nutrition, parenteral nutrition, glucose solutions) These will be compared to the estimated needs of patients and expressed as a % of coverage of these needs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of albuminemia</measure>
    <time_frame>Once a week from admission to discharge (an average of 4 weeks)</time_frame>
    <description>Blood test carried out on admission and once a week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight evolution</measure>
    <time_frame>From admission to discharge (an average of 4 weeks)</time_frame>
    <description>Weighing carried out on admission and on discharge. Will be used to calculate the percentage of weight loss and assess nutritional status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of muscular strength</measure>
    <time_frame>From admission to discharge (an average of 4 weeks)</time_frame>
    <description>Measurements performed at admission and at discharge of the patient. Muscular strength is measured using a dynamometer (in kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of bacteremia and type of germs</measure>
    <time_frame>From admission to discharge (an average of 4 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of transfers to the intensive care unit</measure>
    <time_frame>From admission to discharge (an average of 4 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>From admission to discharge (an average of 4 weeks)</time_frame>
    <description>Number of days of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prokinetic and associated antiemetic treatments</measure>
    <time_frame>From admission to discharge (an average of 4 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type conditioning</measure>
    <time_frame>On admission, between 1 and 7 days before autologous stem cell transplantation</time_frame>
    <description>BEAM or Melphalan 200</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Lymphoma</condition>
  <condition>Myeloma</condition>
  <arm_group>
    <arm_group_label>Patients under the protocol of Enteral Nutrition</arm_group_label>
    <description>Patients put under the protocol of Enteral Nutrition adapted to the conditioning autograft (BEAM or Melphalan 200)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Enteral Nutrition</intervention_name>
    <description>Protocol of Enteral Nutrition adapted to the conditioning autograft (BEAM or Melphalan 200)</description>
    <arm_group_label>Patients under the protocol of Enteral Nutrition</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with lymphoma or myeloma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with lymphoma or myeloma&#xD;
&#xD;
          -  Patient admitted for therapeutic intensification with autologous hematopoietic cells&#xD;
             who are eligible for nutritional support by enteral nutrition&#xD;
&#xD;
          -  Free, informed and written consent signed by the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal of the enteral nutrition&#xD;
&#xD;
          -  All patients with absolute or enteral nutrition contraindications:&#xD;
&#xD;
          -  Digestive fistula&#xD;
&#xD;
          -  Intestinal obstruction&#xD;
&#xD;
          -  Intestinal ischemia&#xD;
&#xD;
          -  Active digestive bleeding&#xD;
&#xD;
          -  Digestive malabsorption (short hail syndrome, bariatric surgery, gastrectomy)&#xD;
&#xD;
          -  Trauma to the base of the skull or significant deviation of the nasal septum not&#xD;
             allowing the insertion of an naso gastric probe.&#xD;
&#xD;
          -  Esophagitis or barrett's esophagus&#xD;
&#xD;
          -  Persistent gastro-duodenal dysfunction (gastroparesis)&#xD;
&#xD;
          -  Patients admitted for autograft for the treatment of conditions other than lymphoma or&#xD;
             myeloma (e. g. solid tumours or leukaemia)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sébastien DAVID</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sébastien DAVID</last_name>
    <phone>+33 (0)5 24 54 91 02</phone>
    <email>david.sebastien@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>François-Xavier GROS</last_name>
    <email>francois-xavier.gros@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH de la Côte Basque</name>
      <address>
        <city>Bayonne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabien PIQUEMAL</last_name>
      <email>fpiquemal@ch-cotebasque.fr</email>
    </contact>
    <contact_backup>
      <last_name>Anne BANOS</last_name>
      <email>abanos@ch-cotebasque.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sébastien DAVID</last_name>
      <email>sebastien.david@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>François-Xavier GROS</last_name>
      <email>francois-xavier.gros@chu-bordeaux.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autologous stem cell transplantation</keyword>
  <keyword>Enteral feeding</keyword>
  <keyword>Myeloma</keyword>
  <keyword>Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

